Table 4

Correlation between the neuropeptide levels and ocular surface evaluation tests/central corneal SBNFL in the study groups

Study variablesSP (ng/mL)NGF (pg/mL)CGRP (ng/mL)VIP (ng/mL)NPY (ng/mL)
Ocular surface evaluation tests
 Group I (antiglaucoma with BAK) (n=82 eyes)
  Mean TBUT (s)−0.05 (0.62)−0.08 (0.46)−0.06 (0.56)0.04 (0.67)−0.07 (0.51)
  Mean Schirmer’s test−0.00 (0.92)−0.01 (0.92)−0.08 (0.47)−0.11 (0.34)−0.04 (0.70)
  Mean corneal staining score0.03 (0.73)0.09 (0.43)−0.10 (0.37)0.10 (0.37)0.10 (0.38)
  Mean conjunctival staining0.09 (0.42)−0.01 (0.91)0.11 (0.32)0.20 (0.86)−0.14 (0.20)
 Group II (antiglaucoma without BAK) (n=71 eyes)
  Mean TBUT (s)−0.02 (0.83)−0.17 (0.18)−0.09 (0.48)0.04 (0.72)0.16 (0.21)
  Mean Schirmer’s test0.11 (0.38)0.02 (0.83)−0.06 (0.62)0.04 (0.71)0.21 (0.09)
  Mean corneal staining score−0.28 (0.02)0.05 (0.67)−0.10 (0.42)0.33 (0.007)−0.10 (0.43)
  Mean conjunctival staining−0.14 (0.27)0.08 (0.49)−0.18 (0.15)0.24 (0.05)0.02 (0.84)
Control eyes (n=30)
  Mean TBUT0.05 (0.78)0.20 (0.26)−0.04 (0.80)0.21 (0.24)−0.06 (0.72)
  Mean Schirmer’s I test−0.00 (0.99)0.02 (0.89)−0.09 (0.61)0.03 (0.87)−0.02 (0.89)
Central corneal SBNFL
 Group I (antiglaucoma with BAK) (n=82 eyes)
  Mean SBNFL density0.02 (0.84)0.04 (0.77)0.14 (0.33)0.06 (0.67)−0.16 (0.25)
  N length0.07 (0.62)0.01 (0.91)0.07 (0.59)0.09 (0.49)−0.10 (0.47)
  N number0.01 (0.91)0.05 (0.71)0.08 (0.58)0.07 (0.59)−0.25 (0.07)
 Group II (antiglaucoma without BAK) (n=71 eyes)
  Mean SBNFL density−0.22 (0.11)0.10 (0.45)0.12 (0.37)−0.29 (0.03)−0.15 (0.26)
  N length−0.12 (0.39)0.10 (0.45)0.05 (0.68)−0.24 (0.08)−0.12 (0.37)
  N number0.00 (0.98)0.08 (0.54)0.20 (0.15)−0.28 (0.04)−0.06 (0.67)
  • Correlation coefficient (*p value) (*Spearman correlation test)

  • BAK, benzalkonium chloride; CGRP, calcitonin gene-related peptide; NGF, nerve growth factor; NPY, neuropeptide Y; SBNFL, subbasal nerve fibre layer; SP, substance P; TBUT, tear breakup time; VIP, vasoactive intestinal peptide.